UB Paderborn / Katalog / Suche / in CDI

1 – 20 von 20

Sortiert nach

Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin

Journal of pharmacokinetics and pharmacodynamics, 2010-02, Vol.37 (1), p.3-24

2010

Volltextzugriff (PDF)

Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer

British journal of cancer, 2018-11, Vol.119 (10), p.1208-1214

2018

Volltextzugriff (PDF)

Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA)

Journal of clinical oncology, 2021-04, Vol.39 (10), p.1108-1118

2021

Volltextzugriff (PDF)

Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's Disease

Clinical pharmacology and therapeutics, 2023-06, Vol.113 (6), p.1258-1267

2023

Volltextzugriff (PDF)

First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma

Clinical cancer research, 2015-02, Vol.21 (3), p.553-560

2015

Volltextzugriff (PDF)

Early change in tumour size predicts overall survival in patients with first-line metastatic breast cancer

European journal of cancer (1990), 2016-10, Vol.66, p.95-103

2016

Volltextzugriff (PDF)

Disease progression model using the integrated Alzheimer's Disease Rating Scale

Alzheimer's & dementia, 2023-06, Vol.19 (6), p.2253-2264

2023

Volltextzugriff (PDF)

Investigating the impact of target lesion selection on drug effect evaluation and tumour growth rate determination using tumour growth inhibition models: Example of malignant pleural mesothelioma patients treated with cisplatin alone or in combination with pemetrexed

European journal of pharmaceutical sciences, 2021-06, Vol.161, p.105781-105781, Article 105781

2021

Volltextzugriff (PDF)

Handling Missing Data in a Duloxetine Population Pharmacokinetic/Pharmacodynamic Model – Imputation Methods and Selection Models

Pharmaceutical research, 2014-10, Vol.31 (10), p.2829-2843

2014

Volltextzugriff (PDF)

Models for change in tumour size, appearance of new lesions and survival probability in patients with advanced epithelial ovarian cancer

British journal of clinical pharmacology, 2016-09, Vol.82 (3), p.717-727

2016

Volltextzugriff (PDF)

A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors

Cancer chemotherapy and pharmacology, 2017-04, Vol.79 (4), p.673-680

2017

Volltextzugriff (PDF)

Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination With Pegilodecakin in Patients With Metastatic NSCLC (CYPRESS 1 and CYPRESS 2)

Journal of thoracic oncology, 2021-02, Vol.16 (2), p.327-333

2021

Volltextzugriff (PDF)

Defining a therapeutic window for the novel TGF‐β inhibitor LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model

British journal of clinical pharmacology, 2014-05, Vol.77 (5), p.796-807

2014

Volltextzugriff (PDF)

Assessment of In Vivo Clinical Product Performance of a Weak Basic Drug by Integration of In Vitro Dissolution Tests and Physiologically Based Absorption Modeling

The AAPS journal, 2015-11, Vol.17 (6), p.1395-1406

2015

Volltextzugriff (PDF)

Population pharmacokinetic modelling of S-warfarin to evaluate the design of drug–drug interaction studies for CYP2C9

Journal of pharmacokinetics and pharmacodynamics, 2012-04, Vol.39 (2), p.147-160

2012

Volltextzugriff (PDF)

Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine

International journal of molecular sciences, 2017-05, Vol.18 (5), p.995

2017

Volltextzugriff (PDF)

Linking preclinical and clinical whole-body physiologically based pharmacokinetic models with prior distributions in NONMEM

European journal of clinical pharmacology, 2007-05, Vol.63 (5), p.485-498

2007

Volltextzugriff (PDF)

Diazepam pharamacokinetics from preclinical to phase I using a bayesian population physiologically based pharmacokinetic model with informative prior distributions in winbugs

Journal of pharmacokinetics and pharmacodynamics, 2006-10, Vol.33 (5), p.571-594

2006

Volltextzugriff (PDF)

A comment on the "correction" of tissue-plasma partition coefficients for drug extraction in eliminating organs by Sven Björkman

Journal of pharmacokinetics and pharmacodynamics, 2005-12, Vol.32 (5-6), p.659-662

2005

Volltextzugriff (PDF)

Vaccines for immunotherapy of breast cancer and prostate cancer: new developments and comparative aspects

In vivo (Athens), 2002-11, Vol.16 (6), p.405

2002

Volltextzugriff (PDF)

1 – 20 von 20

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieCancer Research

ThemaPharmacokinetics

ThemaHumans

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(20)
Mit Volltextzugriff
(19)

Publikationsform

Artikel
(20)

Sprache

Englisch
(20)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(20)
Science & Technology
(20)
Pharmacology & Pharmacy
(12)
Female
(11)
Male
(11)
Adult
(8)
Middle Aged
(7)
Models, Biological
(7)
Oncology
(6)
Aged
(5)
Animals
(5)
Pharmacology/toxicology
(5)
Pharmacy
(5)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(4)
Biochemistry
(4)
Biomedical And Life Sciences
(4)
Biomedicine
(4)
Deoxycytidine - Analogs & Derivatives
(4)
Gemcitabine
(4)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin

Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer

Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA)

Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's Disease

First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma

Early change in tumour size predicts overall survival in patients with first-line metastatic breast cancer

Disease progression model using the integrated Alzheimer's Disease Rating Scale

Investigating the impact of target lesion selection on drug effect evaluation and tumour growth rate determination using tumour growth inhibition models: Example of malignant pleural mesothelioma patients treated with cisplatin alone or in combination with pemetrexed

Handling Missing Data in a Duloxetine Population Pharmacokinetic/Pharmacodynamic Model – Imputation Methods and Selection Models

Models for change in tumour size, appearance of new lesions and survival probability in patients with advanced epithelial ovarian cancer

A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors

Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination With Pegilodecakin in Patients With Metastatic NSCLC (CYPRESS 1 and CYPRESS 2)

Defining a therapeutic window for the novel TGF‐β inhibitor LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model

Assessment of In Vivo Clinical Product Performance of a Weak Basic Drug by Integration of In Vitro Dissolution Tests and Physiologically Based Absorption Modeling

Population pharmacokinetic modelling of S-warfarin to evaluate the design of drug–drug interaction studies for CYP2C9

Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine

Linking preclinical and clinical whole-body physiologically based pharmacokinetic models with prior distributions in NONMEM

Diazepam pharamacokinetics from preclinical to phase I using a bayesian population physiologically based pharmacokinetic model with informative prior distributions in winbugs

A comment on the "correction" of tissue-plasma partition coefficients for drug extraction in eliminating organs by Sven Björkman

Vaccines for immunotherapy of breast cancer and prostate cancer: new developments and comparative aspects

Aktive Filter

Suchergebnisse filtern